| Sheri Lynn Berger, LPN | |
|
2201 Summerlon Cir, Dodge City, KS 67801-2985 | |
| (620) 225-7146 | |
| (316) 469-0805 |
| Full Name | Sheri Lynn Berger |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 2201 Summerlon Cir, Dodge City, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942080163 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 23-21977-082 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sheri Lynn Berger, LPN 2201 Summerlon Cir, Dodge City, KS 67801-2985 Ph: (620) 225-7146 | Sheri Lynn Berger, LPN 2201 Summerlon Cir, Dodge City, KS 67801-2985 Ph: (620) 225-7146 |
News Archive
STRATAGEM COST Action (New diagnostic and therapeutic tools against multidrug resistant tumors) has created a "Task Force" of researchers contributing to Covid-19 research.
Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Epanova™ for the treatment for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).
The molecule NCAM2, a glycoprotein from the superfamily of immunoglobulins, is a vital factor in the formation of the cerebral cortex, neuronal morphogenesis and formation of neuronal circuits in the brain, as stated in the new study published in the journal Cerebral Cortex.
BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020.
› Verified 3 days ago
Jewel Knight, LPN, LMSW Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2201 Summerlon Cir, Dodge City, KS 67801 Phone: 316-641-8678 |